Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Plasma total cell-free DNA is a prognostic biomarker of overall survival in metastatic solid tumour patients

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Eribulin versus dacarbazine in patients with leiomyosarcoma: subgroup analysis from a phase 3, open-label, randomised study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Intratumor heterogeneity of PD-L1 expression in head and neck squamous cell carcinoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Risk of cardiovascular events in men treated for prostate cancer compared with prostate cancer-free men

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Breast cancer mortality in synchronous bilateral breast cancer patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Testing NTRK testing: Wet-lab and in silico comparison of RNA-based targeted sequencing assays

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Variant in ERAP1 promoter region is associated with low expression in a patient with a Behçet-like MHC-I-opathy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Shared heritability and functional enrichment across six solid cancers

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

BACKGROUND: Selecting patients for early clinical trials is a challenging process and clinicians lack sufficient tools to predict overall survival (OS). Circulating cell-free DNA (cfDNA) has recently been shown to be a promising prognostic biomarker. The aim of this study was to investigate whether baseline cfDNA measurement could improve the prognostic information of the Royal Marsden Hospital (RMH) score.

METHODS: Solid tumour patients referred for phase I trials were included in the Copenhagen Personalized Oncology (CoPPO) programme. Baseline characteristics were collected prospectively, including the RMH prognostic score, Eastern Cooperative Oncology Group (ECOG) performance status and concentration of cfDNA per millilitre plasma. Cox proportional hazards model was used to assess the prognostic value of baseline variables.

RESULTS: Plasma cfDNA concentration was quantifiable in 302 patients out of a total of 419 included in the study period of 2 years and 5 months. The RMH score was confirmed to be associated with OS. Cell-free DNA was shown to be an independent prognostic marker of OS and improved the risk model, including RMH, performance status and age. Furthermore, both plasma cfDNA concentration and RMH score were associated with treatment allocation (p < 0.00001).

CONCLUSION: Our model based on RMH score, age, ECOG performance status and cfDNA improved prediction of OS and constitutes a clinically valuable tool when selecting patients for early clinical trials. An interactive version of the prognostic model is published on http://bit.ly/phase1survival .

OriginalsprogEngelsk
TidsskriftBritish Journal of Cancer
Vol/bind121
Udgave nummer2
Sider (fra-til)125-130
Antal sider6
ISSN0007-0920
DOI
StatusUdgivet - jul. 2019

ID: 58968611